tiprankstipranks
Trending News
More News >
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market
Advertisement

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

(2315)

Rating:62Neutral
Price Target:
HK$21.00
▼(-3.45%Downside)
The stock score is primarily supported by strong financial performance, driven by significant revenue growth and improved profitability. Technical analysis suggests a strong upward trend, although the high P/E ratio indicates potential overvaluation. The absence of a dividend yield and earnings call data slightly detracts from the overall score.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model

Company DescriptionBiocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.
How the Company Makes MoneyBiocytogen Pharmaceuticals generates revenue primarily through its contract research services and the development of genetically engineered animal models, which are crucial for drug discovery and development. The company collaborates with pharmaceutical and biotechnology companies, providing them with customized models that aid in the research and testing of new drugs. Additionally, Biocytogen enters into partnerships and licensing agreements to leverage its expertise in gene-editing technologies, further expanding its revenue streams. These collaborations and agreements often involve milestone payments and royalties, which contribute significantly to the company's earnings.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview

Summary
The company has shown significant revenue growth and improved profitability with a positive net income and enhanced EBIT margins. However, the net profit margin remains low, and there is room for improvement in return on equity.
Income Statement
65
Positive
The company has shown significant revenue growth with a 36.8% increase from 2023 to 2024. Gross profit margin is strong at 77.7% for 2024, indicating effective cost management. However, the net profit margin is low at 3.4%, reflecting challenges in profitability despite positive net income in 2024. The EBIT margin improved significantly to 16.8% from a negative position in the previous year.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio is 0.68, indicating a moderate level of leverage. The equity ratio is 34.5%, showing a stable financial structure. Return on equity is modest at 4.0%, suggesting room for improvement in generating returns on shareholders' equity.
Cash Flow
70
Positive
The free cash flow improved to 174.1 million from a negative position in the prior year, with a substantial free cash flow growth rate. The operating cash flow to net income ratio is 6.3, indicating strong cash generation relative to net income. However, stability in cash flow generation should be monitored.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue980.45M716.91M533.88M354.56M253.54M
Gross Profit761.52M506.03M391.75M247.44M166.99M
EBITDA303.80M-97.87M-413.31M-378.12M-318.44M
Net Income33.54M-382.95M-602.16M-585.60M-542.97M
Balance Sheet
Total Assets2.42B2.45B2.80B2.30B2.33B
Cash, Cash Equivalents and Short-Term Investments381.18M434.04M611.27M566.45M950.04M
Total Debt570.28M544.11M415.28M538.35M463.80M
Total Liabilities1.58B1.66B1.65B1.05B868.28M
Stockholders Equity834.06M785.89M1.15B1.25B1.45B
Cash Flow
Free Cash Flow174.12M-203.26M-543.94M-564.45M-531.73M
Operating Cash Flow211.25M-76.65M-303.27M-365.78M-225.31M
Investing Cash Flow-137.12M-100.28M-153.74M-84.13M-188.18M
Financing Cash Flow-92.03M-37.82M587.20M219.44M868.44M

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price21.75
Price Trends
50DMA
18.64
Positive
100DMA
15.53
Positive
200DMA
11.38
Positive
Market Momentum
MACD
0.57
Positive
RSI
54.40
Neutral
STOCH
58.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 21.75 is above the 20-day moving average (MA) of 21.70, above the 50-day MA of 18.64, and above the 200-day MA of 11.38, indicating a neutral trend. The MACD of 0.57 indicates Positive momentum. The RSI at 54.40 is Neutral, neither overbought nor oversold. The STOCH value of 58.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
HK$8.47B235.644.16%34.39%
57
Neutral
HK$8.86B-13.97%-97.81%-117.20%
57
Neutral
HK$9.22B-51.40%58.75%-1310.16%
57
Neutral
£4.81B6.73-62.36%5.45%34.03%6.31%
53
Neutral
HK$12.90B-55.68%-4.33%
51
Neutral
HK$14.04B-18.87%16.35%-49.63%
HK$9.82B111.204.95%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
21.50
14.08
189.76%
HK:1672
Ascletis Pharma, Inc.
11.62
10.54
975.93%
HK:2157
Lepu Biopharma Co. Ltd. Class H
7.94
5.02
171.92%
HK:2162
Keymed Biosciences, Inc.
57.50
25.45
79.41%
HK:2171
CARsgen Therapeutics Holdings Ltd.
24.85
20.32
448.57%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
17.18
8.14
90.04%

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events

Biocytogen Pharmaceuticals Initiates Share Repurchase and Award Scheme
Jun 13, 2025

Biocytogen Pharmaceuticals announced a voluntary share repurchase plan, approved at its 2024 AGM, to buy back up to 11,078,192 H Shares, representing 10% of its H Shares and 2.77% of its total issued share capital, using internal funds up to HK$50 million over the next 24 months. The repurchased shares may be held as Treasury Shares or used for employee share awards, with the company appointing Kastle Limited to manage the repurchase and CMB Wing Lung (Trustee) Limited to oversee the Share Award Scheme, all while adhering to regulatory requirements and market conditions.

Biocytogen Secures Japan Patent for RenMab Platform, Strengthening Global IP Strategy
Jun 5, 2025

Biocytogen Pharmaceuticals has secured a patent in Japan for its RenMab™ fully human antibody mouse platform, marking a significant milestone in its global intellectual property strategy. This achievement enhances the company’s competitive edge in the biotech industry, as the RenMice platform has already generated numerous licensing agreements and high-potential therapeutic candidates, underscoring its substantial commercial value and global recognition.

Biocytogen Pharmaceuticals Concludes Successful 2024 AGM with Strong Shareholder Support
May 28, 2025

Biocytogen Pharmaceuticals held its 2024 Annual General Meeting on May 28, 2025, combining a physical and virtual format. The meeting saw participation from shareholders representing 81.27% of the total voting shares. Key resolutions were voted on, with certain shareholders abstaining due to conflicts of interest, ensuring compliance with regulatory requirements. All resolutions were passed by poll, reflecting strong shareholder support and adherence to corporate governance standards.

Biocytogen Pharmaceuticals Announces 2024 AGM and Key Resolutions
Apr 23, 2025

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for May 28, 2025, which will be held both physically and virtually. The meeting will address key resolutions including the approval of the 2024 annual report, financial statements, and remuneration plans for directors and supervisors. Additionally, a special resolution will be considered regarding the repurchase of H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025